Author
Listed:
- S. P. Rowbotham
(Children’s Hospital Boston
Harvard Medical School)
- F. Li
(New York University Langone Medical Center)
- A. F. M. Dost
(Children’s Hospital Boston
Harvard Medical School)
- S. M. Louie
(Children’s Hospital Boston
Harvard Medical School)
- B. P. Marsh
(Children’s Hospital Boston
Harvard Medical School)
- P. Pessina
(Children’s Hospital Boston
Harvard Medical School)
- C. R. Anbarasu
(Children’s Hospital Boston
Harvard Medical School)
- C. F. Brainson
(University of Kentucky)
- S. J. Tuminello
(Icahn School of Medicine at Mount Sinai)
- A. Lieberman
(Abramson Cancer Center)
- S. Ryeom
(Abramson Cancer Center)
- T. M. Schlaeger
(Children’s Hospital Boston)
- B. J. Aronow
(University of Cincinnati College of Medicine)
- H. Watanabe
(Icahn School of Medicine at Mount Sinai)
- K. K. Wong
(New York University Langone Medical Center)
- C. F. Kim
(Children’s Hospital Boston
Harvard Medical School
Harvard Stem Cell Institute)
Abstract
Epigenetic regulators are attractive anticancer targets, but the promise of therapeutic strategies inhibiting some of these factors has not been proven in vivo or taken into account tumor cell heterogeneity. Here we show that the histone methyltransferase G9a, reported to be a therapeutic target in many cancers, is a suppressor of aggressive lung tumor-propagating cells (TPCs). Inhibition of G9a drives lung adenocarcinoma cells towards the TPC phenotype by de-repressing genes which regulate the extracellular matrix. Depletion of G9a during tumorigenesis enriches tumors in TPCs and accelerates disease progression metastasis. Depleting histone demethylases represses G9a-regulated genes and TPC phenotypes. Demethylase inhibition impairs lung adenocarcinoma progression in vivo. Therefore, inhibition of G9a is dangerous in certain cancer contexts, and targeting the histone demethylases is a more suitable approach for lung cancer treatment. Understanding cellular context and specific tumor populations is critical when targeting epigenetic regulators in cancer for future therapeutic development.
Suggested Citation
S. P. Rowbotham & F. Li & A. F. M. Dost & S. M. Louie & B. P. Marsh & P. Pessina & C. R. Anbarasu & C. F. Brainson & S. J. Tuminello & A. Lieberman & S. Ryeom & T. M. Schlaeger & B. J. Aronow & H. Wat, 2018.
"H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression,"
Nature Communications, Nature, vol. 9(1), pages 1-13, December.
Handle:
RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-07077-1
DOI: 10.1038/s41467-018-07077-1
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-07077-1. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.